医药生物行业周报:并购与授权合作持续活跃,关注创新药领域资源整合加速

上海证券
Jan 27

(以下内容从上海证券《医药生物行业周报:并购与授权合作持续活跃,关注创新药领域资源整合加速》研报附件原文摘录)主要观点近期多起大额交易凸显创新药领域资源整合加速。(1)近日,中国生物制药发布公告,将以总价12亿元人民币,全资收购国内小干扰核酸(siRNA)领域创新药企赫吉亚生物医药有限公司。通过此次收购,中国生物制药将获得siRNA赛道领先的自主技术平台、多元化产品管线及专业研发团队,丰富在大慢病...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10